POsition of Leads in Advanced heaRt Failure: the POLAR Study (POLAR)
2012年1月23日 更新者:Sergio Thal, M.D.
POsition of Leads in Advanced heaRt Failure: the POLAR Study - A 6 Month, Observational, Mult-centered, Blinded, Randomized Study to Determine if Lead Positioning in the Lateral Wall of LV in Patients Meeting Criteria for CRT Plays a Role in Determining Myocardial Function and Affect the Severity of Mitral Regurgitation
The primary objective is to determine if lead positioning in the lateral wall of the left ventricle in patients meeting criteria for cardiac resynchronization therapy plays a role in determining myocardial function and affects the severity of mitral regurgitation.
研究概览
详细说明
This is a 6 month, multi-centered, blinded, randomized study.
Approximately 60 patients will join this study.
Two groups, based on lead position, will be studied with thirty (30) patients randomized into each group.
研究类型
介入性
注册 (预期的)
60
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Arizona
-
Tucson、Arizona、美国、85723
- 招聘中
- Southern Arizona VA Health Care System
-
接触:
- Sergio Thal, M.D.
- 电话号码:4624 520-792-1450
- 邮箱:sergio.thal@va.gov
-
接触:
- Elizabeth Juneman, M.D.
- 电话号码:4624 520-792-1450
- 邮箱:elizabeth.juneman@va.gov
-
首席研究员:
- Sergio Thal, M.D.
-
副研究员:
- Elizabeth Juneman, M.D.
-
副研究员:
- Hoang Thai, M.D.
-
-
Kentucky
-
Lexington、Kentucky、美国、40502
- 招聘中
- Lexington VA Medical Center
-
接触:
- Samy Elayi, M.D.
- 电话号码:859-233-4511
-
首席研究员:
- Samy Elayi, M.D.
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Subject meets the general indications for an implantable cardioverter defibrillator (ICD) with LV systolic function ≤ 35% as defined by echocardiography.
- Subject has moderate or severe heart failure, defined as NYHA Class III-IV for at least 90 days prior to enrollment.
- Subject has optimal pharmacological heart failure therapy for at least 30 days prior to enrollment.
- Subject has a 12-lead electrocardiogram (ECG) obtained no more than 90 days prior to enrollment documenting a sinus rate > 50 bpm and PR interval < 320 ms measured from any two leads.
- 12 lead ECG with left bundle brunch block morphology and a QRS duration of at least 120 msec.
- Subject has creatinine < 2.5 mg/dL obtained no more than 30 days prior to enrollment.
- Subject has left ventricular ejection fraction < 35% by echocardiogram no more than 1 year prior to enrollment.
- Subject is willing and capable of undergoing a device implant and participating in all testing associated with this clinical investigation.
- Subject has a life expectancy of more than 180 days, per physician discretion.
- Subject is age 18 or above, or of legal age to give informed consent specific to state and national law.
Exclusion Criteria:
- Subject has right bundle branch block morphology on a 12-lead ECG obtained no more than 90 days prior to enrollment.
- Subject had previous cardiac resynchronization therapy, a previous coronary venous lead, or meets the general indications for anti-bradycardia pacing defined as ventricular pacing > 40% by pacemaker interrogation.
- Subject has a neuromuscular, orthopedic, or other non-cardiac condition that prevents normal, unsupported walking.
- Subject has an atrial tachyarrhythmia that is permanent (i.e., does not terminate spontaneously and cannot be terminated with medical intervention) or persistent (i.e., can be terminated with medical intervention, but does not terminate spontaneously) within 30 days prior to enrollment.
- Subject currently requires dialysis.
- Subject has severe chronic obstructive pulmonary disease (COPD), defined as FEV1/FVC < 60%, or as defined by a physician.
- Subject has had a myocardial infarction within 30 days prior to enrollment or coronary artery disease (CAD) in which surgical or percutaneous correction was performed within 30 days prior to enrollment.
- Subject has hypertrophic obstructive cardiomyopathy or infiltrative cardiomyopathy (e.g., amyloidosis, sarcoidosis).
- Subject is on IV inotropic agents.
- Subject has any mitral valve prosthesis, or a mechanical aortic or tricuspid prosthesis
- Subject is enrolled in any concurrent study, without Medtronic written approval, which may confound the results of this study.
- Subject is pregnant or planning to get pregnant.
- Subject requires oxygen for medical reasons other than CHF.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Postero-lateral
Left ventricular lateral wall lead position
|
A device implant procedure will be performed under the standard of care technique with the right ventricular lead at the right ventricular apex and the left ventricular lead targeting or postero-lateral area of the LV based on pre-procedure randomization.
|
|
有源比较器:Antero-lateral
Left ventricular lateral wall lead position
|
A device implant procedure will be performed under the standard of care technique with the right ventricular lead at the right ventricular apex and the left ventricular lead targeting or antero-lateral area of the LV based on pre-procedure randomization.
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Change (reduction) in left ventricular end systolic volume (LVESV)
大体时间:3 and 6 months
|
3 and 6 months
|
|
Change in 6 minute walk tests
大体时间:6 weeks, 3 and 6 months
|
6 weeks, 3 and 6 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Myocardial performance as measured by myocardial performance index (MPI)
大体时间:6 months
|
6 months
|
|
|
Papillary muscle velocity as determined by tissue doppler
大体时间:6 months
|
6 months
|
|
|
Progression of mitral regurgitation
大体时间:6 months
|
as measured by regurgitant volume, mitral regurgitation fraction and effective regurgitant orifice area
|
6 months
|
|
Minnesota living heart failure survey
大体时间:6 weeks, 3 and 6 months
|
6 weeks, 3 and 6 months
|
|
|
Chronic heart failure hospitalizations
大体时间:Monitored during study participation ~ 6 months
|
Monitored during study participation ~ 6 months
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Sergio Thal, M.D.、Southern Arizona VA Health Care System
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2010年9月1日
初级完成 (预期的)
2013年3月1日
研究注册日期
首次提交
2012年1月12日
首先提交符合 QC 标准的
2012年1月23日
首次发布 (估计)
2012年1月24日
研究记录更新
最后更新发布 (估计)
2012年1月24日
上次提交的符合 QC 标准的更新
2012年1月23日
最后验证
2012年1月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.